recombinant human alpha galactosidase enzyme replacement therapy (Pharming Group)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant human alpha galactosidase enzyme replacement therapy (Pharming Group)
Drug Alias Nameenzyme replacement therapy (Pharming Group)rhaGAL alpha-galactosidase
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of Actionα-Galactosidase modulators
Targetsα-Galactosidase
Therapy Area/IndicationsGaucher DiseaseFabry DiseaseGlycogen Storage Disease Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPharming Group Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharming Group Nv
Active IndicationsN/A
Inactive IndicationsGaucher DiseaseFabry DiseaseGlycogen Storage Disease Type II

Other Information

ATC CodeN/A
Related LinksN/A